Comparison of effect of Succinylcholine and Cisatracurium on seizure time in electroconvulsive therapy

Comparison of effect of Succinylcholine and Cisatracurium in seizure time in electroconvulsive therapy in children with psychologic disease

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016081229310N1

Enrollment

Registered

2016-09-21

Start date

2016-08-31

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Attention deficit-hyperactivity disorder(ADHD). Condition 2: anorexia nervosa. Condition 3: mental retard. Condition 4: schizophrenia. Condition 5: depression. Condition 6: bipolar disorder. Condition 7: psychosis. Condition 8: conduct disorder. Condition 9: Obsessive-compulsive disorder(OCD). Condition 10: anxiety disorder. Disturbance of activity and attention Anorexia nervosa Mental retardation schizophrenia Depressive episode manic episode acute and transient psychotic d

Interventions

Intervention 1: Group B (the control group): After taking informed consent from patients, an appropriate intravenous (IV) line will be taken and ECG and pulse oximeter and noninvasive blood pressure d

Treatment - Drugs

Group B (the control group): After taking informed consent from patients, an appropriate intravenous (IV) line will be taken and ECG and pulse oximeter and noninvasive blood pressure devices will be a

Group A (intervention group): After taking informed consent from patients, an appropriate intravenous (IV) line will be taken and ECG and pulse oximeter and noninvasive blood pressure devices will be

Eligibility

Sex/Gender

All

Age

No minimum to 25 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients under 25 years who are candidates for electroconvulsive therapy (ECT). Exclusion criteria: persistent medical problems, seizure more than 90 seconds and less than 20 seconds, need to intubation, severe allergy, past history of seizure and epilepsy, addiction to alchohol and drugs.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Duration of seizure. Timepoint: after intervention. Method of measurement: in seconds using a chronometer.;Duration of tonic phase. Timepoint: after intervention. Method of measurement: in seconds using a chronometer.;Duration of clonic phase. Timepoint: after intervention. Method of measurement: in seconds using a chronometer.;Blood Pressure. Timepoint: 1, 5 and 10 seconds after the shock. Method of measurement: mmhg with Manometer.;Pulse. Timepoint: 1, 5 and 10 seconds after the shock. Method of measurement: Beat per minute with Pulse Oximeter.;Beat per minute with Pulse Oximeter. Timepoint: O2 saturation. Method of measurement: Percent with Pulse Oximeter.;Recovery Duration. Timepoint: From the end of seizure to full consciousness. Method of measurement: Minute with Timer.;Back to Breathe Spontaneously. Timepoint: From the end of seizure to respiration. Method of measurement: Second with Timer.	—

Measure

Time frame

Duration of seizure. Timepoint: after intervention. Method of measurement: in seconds using a chronometer.;Duration of tonic phase. Timepoint: after intervention. Method of measurement: in seconds using a chronometer.;Duration of clonic phase. Timepoint: after intervention. Method of measurement: in seconds using a chronometer.;Blood Pressure. Timepoint: 1, 5 and 10 seconds after the shock. Method of measurement: mmhg with Manometer.;Pulse. Timepoint: 1, 5 and 10 seconds after the shock. Method of measurement: Beat per minute with Pulse Oximeter.;Beat per minute with Pulse Oximeter. Timepoint: O2 saturation. Method of measurement: Percent with Pulse Oximeter.;Recovery Duration. Timepoint: From the end of seizure to full consciousness. Method of measurement: Minute with Timer.;Back to Breathe Spontaneously. Timepoint: From the end of seizure to respiration. Method of measurement: Second with Timer.

—

Secondary

Measure	Time frame
Cough. Timepoint: After recovery. Method of measurement: Ask the patient.;Nausea and Vomiting. Timepoint: After recovery. Method of measurement: Ask the patient.;Headache. Timepoint: After recovery. Method of measurement: Ask the patient.;Muscle Pain. Timepoint: After recovery. Method of measurement: Ask the patient.;Laryngospasm. Timepoint: After recovery. Method of measurement: Evaluation of patient such as breathing and o2 sat.	—

Measure

Time frame

Cough. Timepoint: After recovery. Method of measurement: Ask the patient.;Nausea and Vomiting. Timepoint: After recovery. Method of measurement: Ask the patient.;Headache. Timepoint: After recovery. Method of measurement: Ask the patient.;Muscle Pain. Timepoint: After recovery. Method of measurement: Ask the patient.;Laryngospasm. Timepoint: After recovery. Method of measurement: Evaluation of patient such as breathing and o2 sat.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactForough Mirzakhani Hafshejani

Isfahan university of medical sciences

frmirzakhani@gmail.com+98 31 3668 0048

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026